Try our Advanced Search for more refined results
Life Sciences - March, 2015
326 articles
- 11th Circ. Backs Bard In Vein Filter Product Liability Row
- Insmed To Issue $206M In Stock To Fund Inhaled Antibiotics
- Migraine Biotech Heads For $86M IPO With Alternative Drug
- FDA Issues Strongest Warning On Intravenous Anemia Drug
- Cephalon Wants FCA Off-Label Marketing Claims Axed
- Ex-Merck VP Says Investors 'Overstate' Omnicare Impact
- Ranbaxy, AstraZeneca Say Plaintiffs Lack Basis For New Trial
- Fed. Circ. Revives Generic Benicar Exclusivity Challenge
- GSK Urges 3rd Circ. To Nix $121M Damages In Paxil Row
- Biosimilar Patent Disputes — An Update On The Last 8 Months
- Axed Trustees Of Herbalife Founder's Estate Still Fired
- J&J Units, Glaxo Settle False Ad Suit Over Flonase Claims
- Patent For Robotic Pill Dispensing System Ruled Invalid
- Otsuka-FDA Row Tests Potent Anti-Generic Tool
- The 2015 Rising Stars, By Firm
- GNC Deal May Push Retailers To Boost Supplement Testing
- Monsanto, Pfizer Beat PCB Contamination Cost Suit
- EU Requires Antitrust Fixes On $13.4B Zimmer-Biomet Deal
- Novartis, Aduro Ink $750M Cancer Drug Development Deal
- Horizon Pharma To Buy Hyperion Therapeutics For $1.1B
- Bristol-Myers Faces Retaliation Suit After FCA Claims Axed
- Purdue's Sleep Aid Patents Are Obvious, Judge Rules
- FDA Can't Revoke Ranbaxy's Drug Approvals, DC Circ. Told
- MultiVir Eyes Float Amid Stream Of Cancer-Focused IPOs
- Ranbaxy Can't Nix Glass-Tainted Pill Class Action
- Teva To Buy US Biotech Auspex Pharma In $3.2B Drug Merger
- High Court Won't Hear Pliva's Generic Preemption Case
- Mediation And The Thorny Issue Of Settlement Authority
- Teva Impact Will Depend On Phillips Hierarchy Of Evidence
- DOJ Investigation Into Generic Pharma: You Could Be Next
- A-Rod's Cousin Pleads Guilty In MLB Doping Scandal
- Provigil Pay-For-Delay Suit Survives Reconsideration Bid
- Sandoz Can't Dodge Cancer Drug Product Liability Suit
- Insurers Won't Pay For Biotronik's $28M Pacemaker Suit
- Spectrum Pharmaceuticals Stuck With Shareholder Suit
- Medical Products Distributor HSI Protests $68M Tax Bill
- FDA Hears Wide Debate On Generic-Drug Warning Label Plan
- Plaintiffs Blast BioScrip's Use Of Omnicare In Shareholder Suit
- Glucosamine Class Can't Back Out Of $5M Deal, Judge Says
- Law360 Names Top Attorneys Under 40
- GSK Says Calif. Court Should Oversee Abbott HIV-Drug Suit
- Reed Smith Atty To Testify On Novartis Kickback Advice
- Biomet Again Underscores FCPA Risks In Life Sciences
- What Experts Can Say About Inadmissible Facts During Trial
- False Ads Juicing Up Rival's Profits, Supplement Co. Says
- Fed. Circ. Shields Some Patent App Revivals From APA Review
- GNC Asks JPML To Split Supplement MDLs, Consolidate In Pa.
- Deals Rumor Mill: SoftBank, Evonik, Union Bancaire
- Walgreen, Others Sue Over Opana, Solodyn Generic Deals
- Millennium Beats Off-Label Suit, But Free Speech No Factor
- FDA Approves Emergent's Inhalation Anthrax Treatment
- Omnicare Bolsters Case Against Ex-Merck VP, Investors Say
- FDA Rejects Amgen's Biosimilars Info-Sharing Petition
- FedEx Tries To Buck Charges Of Drug Shipping Conspiracy
- Walgreen, Others Sue Over Alleged Aggrenox Pay-For-Delay
- 11th Circ. Won't Revive Chinese Pharma Class Action Claims
- ZS Pharma Eyes $214M Offering To Commercialize Lead Drug
- Ariad, Execs Beat Fraud Suit Over Failed Leukemia Drug
- Utah Bill Targeting Contact Lens Pricing Awaits Gov.'s OK
- Alps Asks Fed. Circ. To Affirm Inequitable-Conduct Ruling
- Kilpatrick Townsend Faces Leaner Drug Device IP Theft Suit
- SEC Nets $18M From Drug Co. Accused Of Duping Investors
- FaegreBD Nabs 9 Partners To Amp Up Chicago Operations
- Jones Day-Led Cellectis Outshines Expectations In US IPO
- High Court May Take On Corporate 5th Amendment Privilege
- FDA Widened Abilify Scope To Admit Generics, Otsuka Says
- Class Cert. Denied In Cephalon Painkiller Marketing Suit
- And Now A Word From The Panel: Just Say No (To MDLs)?
- Supplement Co. Throws Flag On NFL Agent's Double-Dealing
- Cellectis Boosts IPO Target As Immunotherapy Cos. Rally
- Goodwin Procter Leads Blueprint Medicines Toward $100M IPO
- Bristol-Myers Picks Up Autoimmune Research Program
- 3rd Circ. Won't Rehear Relator's FCA Suit Over Drug Costs
- Pharma Patent Rules Give FTC Too Much Clout, DC Circ. Told
- Attys Want 33% Slice Of $1M Pie In PolyMedix Stock Suit
- Biomet's DPA Proves An Inescapable Device
- BPCIA: How Long Is The Party, And Do I Have To Dance?
- Teva, Boehringer Trim 'Frankensteinian' Aggrenox Claims
- DaVita Dodges Dialysis Products Claims
- Pliva Urges Justices To Overturn Iowa Court Generics Ruling
- SEC Says Convicted Atty In NFLer Scam Can't Revisit Ruling
- Deals Rumor Mill: World Duty Free, Warburg Pincus
- Liberty Reaches Deals To Exit Sprawling Meningitis Row
- Contempt Sought In $150M Chinese Vitamin C Antitrust Case
- Patent Troll Bill Embraces 'Political Realism,' Rep. Says
- Fed. Circ. Clips Exela Appeal In Ofirmev Infringement Row
- Contact Lens Antitrust Suits Linked Up In Calif. Court
- USPTO Judge Says Successful IPR Cases Potentially Problematic
- Philly Plaintiffs Free Auxilium From Testim Warranty Claims
- 2 Scientists Guilty Of $10M Gov't Research Grant Fraud
- J&J Wins Battle Over Concerta Patent Ownership
- High Court Won't Hear Stiefel Appeal In $1.5M Share Fight
- Latham & Watkins Adds Another Ex-Finnegan Life Sci Pro
- HHS Fights Court Review In 340B Orphan Drug Row
- 3 Factors Driving The Pharma M&A Surge
- High Court Dumps 1 Of 3 Pa. Reglan Preemption Petitions
- The Law360 400
- A Texas Court's Broad Reading Of FCA Public Disclosure Bar
- Litigation Firms Make Cuts Amid Work Slowdown
- Is MegaLaw Just Big Enough To Fail?
- Law360 Reveals 400 Largest US Firms
- Juror's Google Search May Trigger New Tylenol Death Trial
- Cooley, Maynard Cooper Lead Sluggish Week's 2 IPOs
- Olympus America Hit With 'Superbug' Exposure Suit
- Gilead Attacks FCA Suit's Claims Of Shoddy Drugmaking
- 8 IPOs On Deck To Shatter Lull In New Issuances
- 3 Things To Watch After Sandoz's Biosimilars Win
- FTC To Send Refunds To Body Slimming Cream Customers
- Re-Exam Can't Save Allergan Eye Drop IP, Fed. Circ. Says
- Effexor Buyers Fight To Keep Appeal In 3rd Circ.
- Aveo Kicks Investor Suit Over Losses From Kidney Drugs
- Irish Biotech Malin Raises $357M In IPO For Acquisitions
- 5 Federal Tax Planning Tips For Marijuana Businesses
- Pharmaceutical Co. SteadyMed Misses Target With $40M IPO
- 5 New FCA Rulings Attys Need To Know
- J&J Dodges Claims In 2nd Philly Risperdal Trial
- Gilead Under Fire Again Over New Hepatitis C Program
- Medical Device Companies Face Increased TAA Scrutiny
- Lewis Brisbois Adds IP And Tech Atty To Denver
- 5 Insights From Avon General Counsel Jeff Benjamin
- Another Suit Targets Blood Thinner Xarelto For Side Effects
- Darvocet Plaintiffs Want Suits Sent Back To California
- Sandoz Beats Amgen Bid To Delay Biosimilar Competition
- Heart Monitor Co. To Pay $6.4M To Avoid FCA Overbilling Suit
- Provigil Buyers Drop Fight Over Teva Off-Books Deals
- J&J Buys UK Biopharma Co. To Bolster Cardiovascular Line
- Bristol-Myers Hits Mylan With Suit Over Generic HIV Drug
- Second Philly Risperdal Mass Tort Case Heads To Jury
- FTC, Abbvie Tussle Over Discovery In Pay-For-Delay Suit
- FCA Whistleblowers Poised To Target Post-Employment Fraud
- NJ Supreme Court Clarifies Expert Testimony Rule
- Marshall Gerstein Reels In IP Atty, Technical Specialist
- Post-Grant Proceedings Are Important For Biosimilars
- J&J Unit Stuck With $10M Children's Motrin Verdict
- FTC Backs Christian & Barton Atty For Reckitt Master
- Fed. Circ. Upholds Smith & Nephew's $95M Suture Patent Win
- Ex-NFL Star Gets Mixed Verdict In SEC Pump-And-Dump Suit
- Deals Rumor Mill: Zimmer Holdings, Blackstone Group, Ocwen
- Cancer Treatment Developer Cellectis Fine-Tunes $130M IPO
- Sandoz Gets Investor Suit Over Oriel Buyout Trimmed
- Justices Told $5M IP Award Must Stand Despite Reversal
- DOJ Monitors Biomet For Another Year For FCPA Violations
- Epizyme Eyes $124.5M Offering After Buying Back Cancer Drug
- Cooley Nabs 3 PE, Life Sciences Pros For London Outpost
- Lack Of Off-Label Causation Analysis Could Be Costly
- Valeant Plans $1.45B Stock Offering To Fund Salix Buy
- Teva Will Increase Reliance On Experts In Patent Cases
- Bristol-Myers Gets Relators Booted In Calif. Kickback Suit
- Mass. Beats Most Zogenix Claims Over Painkiller Regulation
- OPINION: Not All That Is Public Should Be Publicized
- Amarin Says FDA Changed Rules To Deny Market Exclusivity
- 2 Drug Developers Latest To Tap Market With $275M On Offer
- Novartis Escapes FCA Suit Over Xolair Marketing
- GSK Found No Asthma Deaths From COPD Drug, FDA Reports
- Merck KGaA Places $4B In Bonds To Fund Sigma-Aldrich Buy
- Contact Lens Cos. Seeing Double As Conspiracy Suits Pile Up
- Drug Giants Commit To $100M Dementia Research VC Fund
- Ex-Employees Accuse Novartis Unit Of Sex Discrimination
- Vital Settles Energy Drink Claims For Price Of 1 Beverage
- Lipitor Buyers Can't Update Pay-For-Delay Suit Again
- Herbalife Investor Suit Crumbles Under Causation Standard
- Life Sciences Cos. See Jump In Securities Suits, Dechert Finds
- Fed. Circ. Will Hear Mylan Hatch-Waxman Jurisdiction Case
- Pfizer's $400M Class Action Settlement Gets Early Nod
- Zimmer Names 3 Bellwether Cases In Knee Implant MDL
- Fed. Circ. Junks $61M Enzo Win In DNA Patent Suit
- 4th Circ. Revives Chelsea Therapeutics Class Action
- National Union Seeks Quick Win In $100M Coverage Dispute
- 3 Ways Valeant Turned Allergan Misfire Into Salix Victory
- Bipartisan House Votes To Speed Up Drug Scheduling
- FTC Says Study Documents Aren't Needed In Actavis Case
- Sandoz Paying $12.6M In Medicare Drug Pricing Dispute
- Pa. Superior Court Affirms $11M Topamax Ruling
- Vitamin Shoppe Says Falsely Labeled Product Doesn't Exist
- IMS Rolls Out €275M Note Offering To Back Cegedim Deal
- Promega: Can Inducer And Infringer Be The Same Party Now?
- Valeant Wins Salix Battle After Upped Bid Makes Endo Bow Out
- IP Boutiques Shrink Amid Litigation Slowdown
- Cancer-Focused Biotechs ViewRay, Xbiotech Join IPO Rush
- Week's Lone IPO Nets $400M As 7 Cos. Promise To Break Lull
- Sandoz ACA Violation Unlikely In Amgen Suit, Judge Says
- Valeant To Raise Salix Offer In Wake Of Endo's Bid
- J&J Units Claim Glaxo Falsely Markets Allergy Med
- Law360's Product-Hopping Cheat Sheet For 2015
- 2nd Circ. Product-Hopping Ruling May Prompt More Suits
- Ackman Says He Didn't Break Law In Anti-Herbalife Campaign
- Judge Bars New Claims In Brown Rudnick Malpractice Row
- PE-Backed Par Pharmaceutical Plans $700M IPO
- Valeant Prices $10.1B Bond Offering To Help Fund Salix Deal
- 5 Insights From Dish General Counsel Stanton Dodge
- Sealed, Signed, Delivered: End Of Mail-Order Pharmacies?
- Execs Name Top Industry Risks In 2015
- J&J, Bard Trial Settlements Show Mesh MDL's Growing Pains
- Experts Limited To 3 In Bard Pelvic Mesh Cases
- Herbalife Rips Ackman's $1B Bet Amid News Of Criminal Probe
- Insurer Gets Fake-Pot Co.'s Policy Rescinded
- 4 Ways Sullivan & Cromwell Can Talk Up Valeant's Salix Bid
- Aduro Becomes Latest Immuno-Oncology Biotech To Plan IPO
- Market Rumors: Integrated Dental, Weststar, Valeant
- FDA Gives Guidance On Cleaning Superbug Scopes
- Hagens Berman Faces Probe Of Thalidomide Client Dismissal
- Big-Name VCs Inject $80M Into Peanut Allergy Treatment
- The 'Palmetto Put-Down' Endangers Drug Cos. Nationwide
- OPINION: Beyond The 'Grow Or Die' Law Firm Model
- Class Action Over Bayer's One-A-Day Labeling Survives
- Mayer Brown, Davis Polk Steer Abbott's $2.5B Notes Offering
- Teva Fights Provigil Attys Over Shielding Settlement Fees
- Jones Day Says Sanctions In Abbott Suit Were Biased
- FDA Beats Ranbaxy Suit Despite 'Serious' Approval Errors
- Texas Pharma Co. Agrees To Pause Drugmaking After Recall
- Judge Issues Rare Injunction In CR Bard Unit's Patent Case
- Kythera Prices $125M Offering After Double-Chin Drug OK'd
- CORRECTED: Report Details $2.3B In 2014 Health Fraud Recovery
- Bidvest, PIC Scope Out Joint Bid For S. African Pharma
- Tracking The Likelihood Of Liability From Health Apps
- Bayer To Spin Off Or List $10B Polymer Biz By 2016
- Endo Confirms $10.6B Salix Bid, Besting Valeant Offer
- Columbia Labs Investors Can't Revive Class Suit In 3rd Circ.
- Zimmer Launches $7.65B Bond Sale To Back Biomet Buy
- VisionAid Insurer Off Hook For Counterclaims In Firing Suit
- Reckitt Must Hand Over Nonprivileged Suboxone Docs To FTC
- FDA Chides Discovery Labs For Dissing Animal Products
- Nutter McClennen Grows IP Practice With Life Sciences Hire
- Ethicon Settles Bellwether Pelvic Mesh Case Mid-Trial
- Dow Corning Asks 6th Circ. To Rehear Breast Implant Suit
- Deals Rumor Mill: KKR, Voith, Dr. Reddy's
- Provigil Attys Look To Shield Fees In Teva Settlements
- Law360 Life Sciences Editorial Advisory Board
- J&J Unit Pleads Guilty Over Children's Tylenol Recall
- State AGs Cracking Down On Herbal Supplement Industry
- Bayer Rice MDL Attys Fight To Keep Fee Class Action Alive
- AltheaDX Nixes IPO As 3 Other Diagnostic Cos. Eye Debuts
- Biopharma Co. Didn't Lie About Cancer Drug Progress: Judge
- 2 Life Sciences Cos. Set Terms Amid Quiet Period For IPOs
- FDA Issues Warning On Seizure, Alcohol Risk With Chantix
- Clearing The Smoke Around The Farr-Rohrabacher Amendment
- Herbalife Says Investor Suit 'Slavishly' Parrots Ackman
- Hagens Berman Leads Suit Alleging Merck Hid Suicide Risks
- Medtronic Hit With FCA Retaliation Suit By Fired Sales Rep
- Ariad Directors Beat Investor Suit Over Failed Leukemia Drug
- Contact Lens Cos. Face Collusion Suit From Indirect Buyers
- GE Shakes Imaging Drug Deal Antitrust Suit In 9th Circ.
- Nicholson & Eastin Can't Rep FCA Whistleblowers, Judge Says
- HHS Watchdog Pressed On New Health Fraud Safe Harbors
- Insurers Needn't Defend Anda In W.Va. 'Pill Mill' Suit
- Ex-U. Miami Coach To Plead Guilty In Doping Case
- Hagens Berman Sanctioned For Bad Thalidomide Suits
- 3rd Circ. Urged To Rehear FCA Suit Over Drug Costs
- Ackman Bets $3B On Former Buyout Partner Valeant
- High Court Asked To Review After-Acquired Evidence Use
- Hedge Fund's AIA Attack Should Have Biotech Cos. Wary
- Concordia Puts Up $1.2B For PE-Backed Drugmaker
- Early Lessons From The REMS Battlefield
- Amazon Sued Over Teen's Death From Caffeine Overdose
- FTC Orders Divestitures In Impax's $700M CorePharma Buy
- Pharm Co. Plans to Appeal Class Cert. In Antitrust MDL
- March Starts Quietly With 2 IPOs, But Forecast Still Strong
- Contact Lens Pricing Suits To Test Landmark Leegin Case
- Taxation With Representation: Wachtell, Gibson, Baker
- 3rd Circ. Declines To Hear Mylan, Celgene Antitrust Fight
- Genentech Blood Cancer IP Not Double-Patented, Judge Rules
- J&J Unit Urges Fed. Circ. To Revive Covidien Patent Suit
- TWi Tells Fed. Circ. Takeda's Dexilant Patent Claims Are Invalid
- Developer Must Face Pisgah's $100M Anti-Abuse Vicodin Suit
- FDA Approves 1st Biosimilar But Punts On Naming Guidance
- The Daimler Confusion And Its Impact On ANDA Litigation
- Suspect In MLB Doping Scandal Moves To DQ Atty
- 5 Tricky Questions To Test Your Drug-Label Law Savvy
- J&J, Ethicon Hit For $5.7M In Calif. Pelvic Mesh Trial
- Bard Tells Fed. Circ. Not To Eye Willfulness In $1B IP Case
- Akorn Hid Delays Integrating VersaPharm, Shareholder Says
- Martek Escapes Injunction In Baby Formula Antitrust Suit
- Paul Hastings Hires Co-Head Of Fried Frank's M&A Practice
- Walgreens, Safeway Want To Join Lidoderm MDL
- USTR Prods 'Notorious' Piracy Markets To Reform
- Intercept Can't Dodge Investors' Stock Drop MDL
- Spain Probes Pfizer For Blocking Parallel Imports
- Fried Frank Hires Ex-Patterson Belknap IP Pro In NY
- Aussie Consumer Watchdog Probes OTC Pain Meds
- Gilead Digs In For High Court Double-Patent Appeal
- Ohio Gets Help In Heroin Epidemic With Rebates On Treatment
- Growth-Minded AMAG Pharma Closes $201.2M Stock Offering
- Mallinckrodt Puts Up $2.3B For PE-Backed Lung Drug Outfit
- A Riegel Analysis From The Great Northwest
- Law Firm Tensions Mount In Africa — What Does It Mean?
- Wachtell Guides AbbVie In $21B Pharmacyclics Buy
- Teva Gets Warner Chilcott's Atelvia Patents Invalidated
- Provigil Buyers Say Teva Coercing Distributors To Pare Suit
- NJ Patent Suits Jump As Pharma Cos. Battle Closer To Home
- Celgene Hit With Suit For Blocking Generic Cancer Drugs
- Novartis Told To Produce Docs In Kickbacks Suit By March 13
- Jones Day Scoops Ex-Roetzel FDA Pro In Miami
- Sanofi Pushes 3rd Circ. To Toss Junk Fax Class Action
- Blackstone-Backed Catalent Eyes $699M In Upsized Offering
- Takeda Dodges Doc Destruction Claims In Wis. Actos Suit
- J&J, Others Sued Over Alleged Contact Lens Price Floors
- 5th Circ. Says Paxil Heart Damage Suit Brought Too Late
- Cleary Gottlieb Leads Actavis In $21B Debt Offering
- How Mayo, Myriad And Alice May Impact Patent Valuations
- Calif. Appeals Court Upholds Breg Win In Pain Pump Suit
- Paul Weiss Rips Med. Co. Liquidator Push For Privileged Docs
- Patent Vet Jumps From Frommer Lawrence To Garson Segal
- EU High Court To Weigh Antitrust Limits To Patent Deals
- FCPA Self-Reporting Brings Benefits: SEC Enforcement Chief
- 2nd Circ. Agrees To Speed Actavis Product-Hopping Hearing
- Med Device Maker Stryker Boosts Share Buybacks To $2.6B
- DOD Awards $430M Surgical Robotics Contract
- Market Rumors: Actavis, HKBN, Aldermore
- Recruiter For Miami Doping Scandal Sentenced To 3 Months
- Viking Recalibrates Drug Focus In New IPO Plans
- FDA Slaps New Warnings On Testosterone Drugs
- The FDA's Vision For Medical Devices Is Coming To Life
- 4th Circ. Upholds J&J Win In Vaginal Mesh Bellwether Case
- Pharmas Fail To Nix Cohen Milstein's Contract With Chicago
- Supplement Maker Vitacost Settles Workout Drink Patent Tiff
- Fed. Circ. Lops Lost Profits Off $101M Medtronic Patent Verdict
- PacWest Ponies Up $849M In Stock For Square 1
- Costco Says J&J Blocked Contact Lens Discounts
- Cygnus Urges Fed. Circ. To Revive Medtrica Patent Row
- Panel Tosses Law Firm's SLAPP Defense To Malpractice Claim
- J&J May Continue Divestiture Trend With $2B Cordis Offer
- Billion-Dollar Issues Loom Over Fla. Legislature Session
- J&J Unit LifeScan Settles Diabetes Product Patent Dispute
- Boston Scientific To Pay $1.6B For Endo Urology Portfolio
- Judge Nixes Class Cert. In Vital Redline Energy Drink Suit
- Actavis Plots Another Offering To Back $66B Allergan Deal